白内障
医学
地塞米松
入射(几何)
眼睑炎
颅面
儿科
共病
青光眼
眼科
病因学
风险因素
眼病
视力
作者
Rahul Kumar Banerjee,Jay Hydren,Jorge Arturo Hurtado Martínez,Mason Barnes,Patricia Alejandra Flores Pérez,Jennifer M. Ahlstrom,Kara I. Cicero,Gurbakhash Kaur,Parisa Taravati,Andrew J. Cowan
标识
DOI:10.1093/oncolo/oyag458
摘要
Both advancing age and multiple myeloma (MM) therapies such as belantamab mafodotin or dexamethasone can be risk factors for ocular complications. We conducted an international online survey of 508 patients with MM; 3% and 2% reported previous craniofacial radiation therapy or belantamab mafodotin, respectively. Common ocular comorbidities included cataracts (59%), dry eyes requiring eyedrops (37%), and blepharitis or styes (24%). Higher typical dexamethasone doses (≥20 milligrams weekly) were associated with cataracts after adjusting for advancing age and time since diagnosis. Compared to lower-dose dexamethasone (0-19 milligrams weekly), high-dose dexamethasone shifted the incidence curve of predicted cataracts approximately 5.4 years earlier. Although 82% of patients reported periodic eye exams (in line with ophthalmologic recommendations for older adults), only 31% had ever received such guidance from their MM teams. In conclusion, ocular issues are common in MM. Corticosteroid-sparing regimens may warrant attention across the age spectrum to reduce the risk of cataracts.
科研通智能强力驱动
Strongly Powered by AbleSci AI